Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 44

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 44
---
 the vesting period. Performance Share Units Our Board of Directors and Compensation Committee include Performance Share Units in the mix of equity awards to the Company’s CEO, other NEOs and other executive officers to increase the relative weighting of performance-based compensation and to tie a more significant portion of total executive officer compensation to the achievement of performance goals that we believe drive the fundamentals of our business. Accordingly, all NEOs and other executive officers, in addition to receiving a grant of stock options and restricted stock units, received a portion of their equity award in the form of performance share units. Consistent with our emphasis on aligning pay for performance, each executive’s awarded performance share units vest upon the achievement of specific individual performance objectives, which are designed to support the long-term performance of the Company. Each of the performance share units have an objective that must be achieved within a defined performance period that must expire after no more than ten years. In connection with the foregoing, on February 22, 2024, Mr. Khattar received a grant of 193,200 performance share units, Mr. Dec received a grant of 12,000 performance share units, Dr. Bhatt received a grant of 5,000 performance share units, and Dr. Rubin and Mr. Mottola each received grants of 7,500 performance share units. Mr. Khattar’s grant of performance share units was increased in 2024 as compared to 2023 because the Committee believes this increase in equity tied to the achievement of performance goals will provide increased focus on Company performance and drive the fundamentals of the Company’s business. On June 24 2024, the Compensation Committee, based on a recommendation from the CEO, established individual performance objectives for each executive and determined that the achievement of each objective would result in the vesting of a specified portion of the performance share units. 28 • With respect to Mr. Khattar: • Exceed non-GAAP operating earnings or net product sales guidance issued by the Company at the beginning of the year by a specified percentage for 2024 and 2025 combined; • Obtain approval from the FDA of SPN-830 no later than a specified period; • Generate a new compound hit from the new discovery platform by December 2025; • File a new patent application for one of the new chemical entities from the discovery platform by 2027; • Execute a corporate development transaction with specified characteristics (a “Corporate Development Transaction”) during 2025; and • Achieve positive Phase II data on SP